Share on LinkedInShare on LinkedIn

ARTICLE · 15 AUGUST 2024

Ferring v Finch: Ripples From The Decision

This decision, laid down by a jury in a federal trial in Delaware on 9 August 2024, concluded with an award of $25 million in damages and future royalties to be paid to Finch.

United StatesIntellectual Property

Three patent claims, one present in each of three US patents held by the Finch Therapeutics Group Inc. (Finch), have been found to have been infringed by Ferring Pharmaceuticals Inc.'s (Ferring) activities in the US and relating to their enema IMT product, REBYOTA®.

This decision, laid down by a jury in a federal trial in Delaware on 9 August 2024, concluded with an award of $25 million in damages and future royalties to be paid to Finch.

Commercial-IP strategies are almost never won or lost in a single court skirmish, but what might this practically mean for Ferring, for Finch, and indeed the wider community of microbiome therapeutic developers?

These proceedings were first brought by Ferring in December, 2021to request a judgement of invalidity or non-infringement for seven patents held by Finch. Presumably, this was part of a strategy to "clear the way" in the US for the launch of their REBYOTA® product, a product that was approved for sale in the US by the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from